Thalidomide in Crohn disease and the risk of peripheral neuropathy

Journal of Pediatric Gastroenterology and Nutrition

Volumn 37, Issue 4, 2003, Pages 522-

  Ahmed, M ^a   El Hadi, S ^a   Jenkins, H R ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG INDICATION; GRANULOMATOSIS; HUMAN; LETTER; NERVE CONDUCTION; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TERATOGENICITY; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; CHILD;

CHILD; CROHN DISEASE; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; THALIDOMIDE;

EID: 1542540209     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200310000-00023     Document Type: Letter

References (4)

1. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
2. Odeka EB, Millar V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 1997;25:250-1.
3. Soler RA, Migliorati C, van Waes H, et al. Thalidomide treatment of mucosal ulcerations in HIV infection. Arch Dis Child 1996;74:64-5.
4. Facchini S, Candusso M, Martelossi S, et al. Efficacy of long term treatment with thalidomide in children and young adults with Crohn's disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32:178-81.